Celcuity Inc
CELC99.740USD
-0.180-0.18%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
4.32BMarket Cap
LossP/E TTM
More Details of Celcuity Inc Company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Celcuity Inc Info
Ticker SymbolCELC
Company nameCelcuity Inc
IPO dateSep 20, 2017
CEOSullivan (Brian F)
Number of employees87
Security typeOrdinary Share
Fiscal year-endSep 20
Address16305 36th Ave N Ste 100
CityMINNEAPOLIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55446-4285
Phone17633920767
Websitehttps://www.celcuity.com/
Ticker SymbolCELC
IPO dateSep 20, 2017
CEOSullivan (Brian F)
Company Executives of Celcuity Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
+3.18%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
+3.18%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
17.11%
Sullivan (Brian F)
6.75%
Perceptive Advisors LLC
6.39%
New Enterprise Associates (NEA)
4.63%
The Vanguard Group, Inc.
4.45%
Other
60.67%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
17.11%
Sullivan (Brian F)
6.75%
Perceptive Advisors LLC
6.39%
New Enterprise Associates (NEA)
4.63%
The Vanguard Group, Inc.
4.45%
Other
60.67%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.24%
Investment Advisor
23.81%
Individual Investor
10.32%
Investment Advisor/Hedge Fund
9.98%
Private Equity
6.79%
Research Firm
5.83%
Venture Capital
5.21%
Corporation
0.76%
Pension Fund
0.18%
Other
2.89%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
306
39.76M
85.92%
-806.98K
2025Q3
298
39.50M
98.78%
+3.79M
2025Q2
215
31.87M
95.31%
+797.76K
2025Q1
207
31.06M
92.46%
-3.93M
2024Q4
197
30.50M
91.70%
-18.57K
2024Q3
181
30.14M
86.73%
+764.96K
2024Q2
164
29.36M
68.66%
+7.16M
2024Q1
155
22.20M
60.61%
+3.55M
2023Q4
137
16.81M
74.10%
+667.49K
2023Q3
139
16.14M
75.21%
+1.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
7.92M
17.11%
+170.10K
+2.20%
Sep 30, 2025
Sullivan (Brian F)
3.12M
6.75%
+96.19K
+3.18%
Sep 30, 2025
Perceptive Advisors LLC
2.96M
6.39%
+285.72K
+10.70%
Sep 30, 2025
New Enterprise Associates (NEA)
2.14M
4.63%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.06M
4.45%
+391.26K
+23.46%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.04M
4.42%
+174.80K
+9.35%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.27M
2.74%
+743.94K
+142.39%
Sep 30, 2025
Laing (Lance G Ph.D.)
1.25M
2.7%
--
--
Sep 30, 2025
Soleus Capital Management, L.P.
1.18M
2.55%
-1.83M
-60.86%
Sep 30, 2025
Tang Capital Management, LLC
1.15M
2.49%
+1.15M
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
5.06%
Virtus LifeSci Biotech Clinical Trials ETF
4.16%
Tema Oncology ETF
3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
3.35%
ALPS Medical Breakthroughs ETF
1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
0.89%
iShares Micro-Cap ETF
0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
0.26%
Vanguard US Momentum Factor ETF
0.16%
State Street SPDR S&P Biotech ETF
0.15%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion5.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion4.16%
Tema Oncology ETF
Proportion3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion3.35%
ALPS Medical Breakthroughs ETF
Proportion1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.89%
iShares Micro-Cap ETF
Proportion0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.26%
Vanguard US Momentum Factor ETF
Proportion0.16%
State Street SPDR S&P Biotech ETF
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Celcuity Inc?
The top five shareholders of Celcuity Inc are:
Baker Bros. Advisors LP holds 7.92M shares, accounting for 17.11% of the total shares.
Sullivan (Brian F) holds 3.12M shares, accounting for 6.75% of the total shares.
Perceptive Advisors LLC holds 2.96M shares, accounting for 6.39% of the total shares.
New Enterprise Associates (NEA) holds 2.14M shares, accounting for 4.63% of the total shares.
The Vanguard Group, Inc. holds 2.06M shares, accounting for 4.45% of the total shares.
Baker Bros. Advisors LP holds 7.92M shares, accounting for 17.11% of the total shares.
Sullivan (Brian F) holds 3.12M shares, accounting for 6.75% of the total shares.
Perceptive Advisors LLC holds 2.96M shares, accounting for 6.39% of the total shares.
New Enterprise Associates (NEA) holds 2.14M shares, accounting for 4.63% of the total shares.
The Vanguard Group, Inc. holds 2.06M shares, accounting for 4.45% of the total shares.
What are the top three shareholder types of Celcuity Inc?
The top three shareholder types of Celcuity Inc are:
Baker Bros. Advisors LP
Sullivan (Brian F)
Perceptive Advisors LLC
Baker Bros. Advisors LP
Sullivan (Brian F)
Perceptive Advisors LLC
How many institutions hold shares of Celcuity Inc (CELC)?
As of 2025Q4, 306 institutions hold shares of Celcuity Inc, with a combined market value of approximately 39.76M, accounting for 85.92% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -12.85%.
What is the biggest source of revenue for Celcuity Inc?
In --, the -- business generated the highest revenue for Celcuity Inc, amounting to -- and accounting for --% of total revenue.
